Privium Fund Management B.V. Autolus Therapeutics PLC Transaction History
Privium Fund Management B.V.
- $354 Million
- Q2 2024
A detailed history of Privium Fund Management B.V. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Privium Fund Management B.V. holds 160,639 shares of AUTL stock, worth $559,023. This represents 0.16% of its overall portfolio holdings.
Number of Shares
160,639
Previous 50,058
220.91%
Holding current value
$559,023
Previous $319,000
75.24%
% of portfolio
0.16%
Previous 0.09%
Shares
7 transactions
Others Institutions Holding AUTL
# of Institutions
114Shares Held
167MCall Options Held
34.2KPut Options Held
19.5K-
Syncona Portfolio LTD Guernsey, Channel Islands, X021.3MShares$74.3 Million86.45% of portfolio
-
Blackstone Inc New York, NY20.5MShares$71.3 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA17.9MShares$62.3 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$53.1 Million1.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$43 Million0.59% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $316M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...